This is the reality check , Stuart Lucas was senior MD of Bear Stearns for 6 years , MD of Prudential for 5 years ,MD of Nomura for 4 years ,before starting the highly successful Asset Match , he has invested over £500k in this company. Now who would you want to follow Mr Lucas or a trader who try’s to make 20quid on a 50. Quid punt , I know where my money is staying .!
“On the evening of July 29, Byhealth Co., Ltd. (300146.SZ, hereinafter referred to as "Byhealth" or "the Company") disclosed the 2020 semi-annual performance report. According to the report, the Company's operating revenue from January to June this year was 3.125 billion Yuan, a year-on-year increase of 5.23%, and the net profit attributable to shareholders of listed company was 962 million Yuan, a year-on-year increase of 10.96%. As a global leader in Vitamin & Dietary Supplements (VDS), Byhealth has overcome several external adverse factors, shown steady momentum and sustained growth in the 2020 semi-annual examination.”
Since the outbreak of COVID-19, the domestic consumer market has been impacted to varying degrees. As Byhealth stated in the report, due to the pandemic, the Company's production, marketing, and new product launch in the first half of the year have been delayed compared to the normal schedule, and the off-line business of the Company has also been affected to a certain extent. In the first half of the year, the Company's domestic off-line channel revenue fell by 4.35% year-on-year, while on-line business achieved rapid growth, with domestic on-line channel revenue increased by 46.83% year-on-year. Despite the global spread of the COVID-19 and the existence of repeated outbreak in Australia, the development of cross-border e-commerce platforms has brought new impetus to the business growth of LSG in Australia. In the first half of the year, LSG's overseas business achieved operating income of A$66 million, a year-on-year increase of 16.74%, and a year-on-year increase of 30.73% after the inter-segment offset. “
PHDS enjoys a high reputation and widespread acclaim for successful registration experience in China for over 25 years for health food, dietary supplement, food ingredients and GRAS products. PHDS provides high quality, high efficiency and reliable service of regulatory consulting and registration for clients from over 54 countries. As an expert in regulatory affairs in China, PHDS possesses enormous successful registration experience for health food.
The regulatory management of China's dietary supplement industry has always been a controversial issue especially over the pasted years. CFDA requires companies to apply for a registration before marketing. The registration is referred to as a "blue hat" registration because the logo resembles a blue hat. Most registration could cost upwards of $100,000 or more per product depending on what claim is being made and what the ingredients are, then various laboratory tests and animal tests would be taken. Since the issue of Health Food Registration and Filing Management Procedure, the products that meet the requirements of specific ingredients and usage can go throug a filing procedure, which is called a "orange hat". PHDS as a leading professional expert in such regulatory affairs has a very high efficient and high successful rate for the registration with CFDA.
And this statement has been an ever present . “ ). China is now the world's second-largest pharmaceuticals market, measured by how much patients and the state spend on drugs (source: health-care information company IQVIA). The Company believes that Fruitflow has the potential to play an important role in the Chinese cardiovascular health market.“
Perhaps the bod also see this as a way of achieving this statement “ The Company and DSM are keen to secure greater medical advocacy for Fruitflow® and the roundtable event forms part of this strategy.”